October 19, 2009 (FinancialWire) -- Generex Biotechnology Corp. (NASDAQ: GNBT | Quote | Chart | News | PowerRating) (www.generex.com), a leader in drug delivery for metabolic diseases through the inner lining of the mouth, at a conference in Oran, Algeria, Generex, together with Continental Pharma Laboratories, the company's importation, marketing, distribution, and sales agent in Algeria, announced the launch of commercial sales of Generex Oral-lyn in Algeria.
The product has been approved for importation and commercial marketing and sale in Algeria, and will be marketed and sold for the treatment of patients with Type-1 or Type-2 diabetes. The size of the diabetes population in the Eastern Mediterranean and Middle East region is approximately 24,500,000.
The launch of Generex Oral-lyn took place at Royal Hotel, Oran.
FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.
Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).
http://www.financialwire.net

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index